Vivian Lin

P21 - ECE_2037 - Crinecerfont improves cardiometabolic outcomes associated with chronic supraphysiologic glucocorticoid exposure: 1-year results from CAHtalyst™ adult

Oksana Hamidi, Irina Bancos, Deborah Merke, Nicole Reisch et autres

Abstract Background Chronic exposure to supraphysiologic glucocorticoid (GC) doses can adversely impact cardiometabolic health. Crinecerfont is FDA-approved as an adjunct to GC replacement to control androgens in patients with classic congenital adrenal hyperplasia (CAH), enabling GC dose reduction. Changes in GC dose …

us, de, fr, gb (code pays fourni par la source)

OC9.5 - ECE_2036 - Adults with classic congenital adrenal hyperplasia taking crinecerfont demonstrated sustained decreases in glucocorticoid doses: 2-year results from the CAHtalyst™ adult study

Irina Bancos, Oksana Hamidi, Florian Kiefer, Rosario Pivonello et autres

Abstract Background Crinecerfont is a novel corticotropin releasing factor type 1 receptor (CRF1) antagonist that is FDA-approved as an adjunct to glucocorticoid (GC) replacement to control androgens in patients (≥4 years) with classic congenital adrenal hyperplasia (CAH). This study evaluated changes in …

us, at, it, gb, fr (code pays fourni par la source)

PCR67 A CROSS-SECTIONAL SURVEY ON CRINECERFONT AND QUALITY OF LIFE OF ADULTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH) IN THE UNITED STATES (US) PARTICIPATING IN CAHTALYST ADULT OPEN-LABEL EXTENSION (OLE) STUDY

Sonal Vaid, Jessica D. Abramowitz, Irina Bancos, Henry Kim Cheng et autres

us (code pays fourni par la source)